The drop comes the day after the drugmaker said it would add a so-called black-box warning to its gene therapy Elevidys after ...

The FDA will request Sarepta Therapeutics stop all shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, ...

Sarepta Therapeutics (SRPT) stock falls as the FDA reviews if the company's gene therapy Elevidys should remain on the market following patient deaths. Read more here.

Shares of Sarepta Therapeutics plunged more than 30% on Friday as the future of its key gene therapy treatment appeared at ...

Sarepta Therapeutics was approached for comment by Clinical Trials Arena but did not respond before publication. This comes after two deaths were announced following treatment wit ...

The U.S. Food and Drug Administration will request Sarepta Therapeutics to voluntarily stop all shipments of its gene therapy ...

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

A 51-year-old man with limb-girdle muscular dystrophy died after receiving Sarepta's experimental gene therapy and experiencing acute liver failure.

The death will likely further stoke safety concerns around Sarepta's gene therapies, as well as raise questions around the ...

A third patient has died from acute liver failure after receiving a gene therapy treatment from Sarepta Therapeutics, the biotech company confirmed to Bloomberg on July 18. The patient died while ...

While the previous two deaths occurred in patients treated with Elevidys, the most recent patient was receiving one of ...

Shares of Sarepta Therapeutics declined 17% in early trading on Friday after a patient who had received one of the company's experimental gene therapies died, deepening investor concern over the use ...